{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "COVID-19 treatment", "IL-1 antagonist", "IL-6 antagonist", "Interleukins", "anakinra", "tocilizumab"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37046952", "DateRevised": {"Year": "2023", "Month": "04", "Day": "15"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "04", "Day": "03"}], "Language": ["eng"], "ELocationID": ["1025", "10.3390/healthcare11071025"], "Journal": {"ISSN": "2227-9032", "JournalIssue": {"Volume": "11", "Issue": "7", "PubDate": {"Year": "2023", "Month": "Apr", "Day": "03"}}, "Title": "Healthcare (Basel, Switzerland)", "ISOAbbreviation": "Healthcare (Basel)"}, "ArticleTitle": "A Prospective Cohort Study of COVID-19: Evaluation of the Early Role of IL-1 and IL-6 Antagonists in Improving the Outcome of the Illness and Reduction in the Risk of Death.", "Abstract": {"AbstractText": ["The COVID-19 pandemic had a profound impact on global health, economies, and social systems. The crucial factor that determines the success of COVID-19 treatments is preventing the need for mechanical ventilation and intensive care admission. In the context of COVID-19, several treatments have been found to play a role in the disease's progression and severity. Interleukins (ILs) have been identified as key mediators of the cytokine storm that can occur in severe cases of COVID-19, leading to respiratory failure and other complications. For instance, IL-1 antagonist (anakinra) and IL-6 antagonist (tocilizumab) are supposed to be promising treatments as well as cortisones for COVID-19. This prospective study aims to evaluate the effectiveness of anakinra or tocilizumab in addition to cortisone in preventing the progression of mild to moderate COVID-19 cases to severe intensive care admission. Biochemical and hematological parameters, such as D-dimer, ferritin, LDH, CRP, and white blood cells (WBCs), were measured after treatment with either anakinra or tocilizumab in addition to cortisone or cortisone alone. The study also recorded the number of deaths and patients admitted to intensive care. The results indicate that anakinra significantly improved outcomes and decreased the number of intensive care admissions compared to tocilizumab or cortisone alone. Therefore, anakinra may play a vital role in controlling the progression of COVID-19, and its use in mild to moderate cases may prevent the worsening of the disease to severe stages."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Field Hospital, Muscat 111, Oman."}], "LastName": "Al Kharusi", "ForeName": "Mardheya", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Field Hospital, Muscat 111, Oman."}], "LastName": "Al Sheikh", "ForeName": "Naffesa", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Field Hospital, Muscat 111, Oman."}], "LastName": "Alhajri", "ForeName": "Maiya", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy Department, Field Hospital, Muscat 111, Oman."}], "LastName": "Al Mandhri", "ForeName": "Seif Ali", "Initials": "SA"}, {"Identifier": ["0000-0002-3741-0893"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt."}], "LastName": "Khafagy", "ForeName": "El-Sayed", "Initials": "ES"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Al-kharj 11942, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Microbiology and Parasitology, Medicinal and Aromatic Plants Research Institute, National Center for Research, Khartoum 2404, Sudan."}], "LastName": "Moglad", "ForeName": "Ehssan H", "Initials": "EH"}, {"Identifier": ["0000-0003-2821-9373"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia."}], "LastName": "Alotaibi", "ForeName": "Hadil Faris", "Initials": "HF"}, {"Identifier": ["0000-0001-5683-4803"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Microbiology and Immunology, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt."}, {"Identifier": [], "Affiliation": "Pharmacy Program, Department of Pharmaceutical Sciences, Oman College of Health Sciences, Muscat 113, Oman."}], "LastName": "Hegazy", "ForeName": "Wael A H", "Initials": "WAH"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Healthcare (Basel)", "NlmUniqueID": "101666525", "ISSNLinking": "2227-9032"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "V\u2019Kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155\u2013170. doi: 10.1038/s41579-020-00468-6.", "ArticleIdList": ["10.1038/s41579-020-00468-6", "PMC7592455", "33116300"]}, {"Citation": "Yang H., Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685\u2013700. doi: 10.1038/s41579-021-00630-8.", "ArticleIdList": ["10.1038/s41579-021-00630-8", "PMC8447893", "34535791"]}, {"Citation": "Zhang H.P., Sun Y.L., Wang Y.F., Yazici D., Azkur D., Ogulur I., Azkur A.K., Yang Z.W., Chen X.X., Zhang A.Z., et al. Recent developments in the immunopathology of COVID-19. Allergy. 2023;78:369\u2013388. doi: 10.1111/all.15593.", "ArticleIdList": ["10.1111/all.15593", "36420736"]}, {"Citation": "Cao Z., Gao W., Bao H., Feng H., Mei S., Chen P., Gao Y., Cui Z., Zhang Q., Meng X., et al. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of COVID-19. N. Engl. J. Med. 2023;388:406\u2013417. doi: 10.1056/NEJMoa2208822.", "ArticleIdList": ["10.1056/NEJMoa2208822", "PMC9812289", "36577095"]}, {"Citation": "Muralidar S., Ambi S.V., Sekaran S., Krishnan U.M. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 2020;179:85\u2013100. doi: 10.1016/j.biochi.2020.09.018.", "ArticleIdList": ["10.1016/j.biochi.2020.09.018", "PMC7505773", "32971147"]}, {"Citation": "Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3\u201320. doi: 10.1038/s41580-021-00418-x.", "ArticleIdList": ["10.1038/s41580-021-00418-x", "PMC8491763", "34611326"]}, {"Citation": "Kirtipal N., Bharadwaj S., Kang S.G. From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses. Infect. Genet. Evol. 2020;85:104502. doi: 10.1016/j.meegid.2020.104502.", "ArticleIdList": ["10.1016/j.meegid.2020.104502", "PMC7425554", "32798769"]}, {"Citation": "Jayaweera M., Perera H., Gunawardana B., Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ. Res. 2020;188:109819. doi: 10.1016/j.envres.2020.109819.", "ArticleIdList": ["10.1016/j.envres.2020.109819", "PMC7293495", "32569870"]}, {"Citation": "Botta M., Caritg O., van Meenen D.M.P., Pacheco A., Tsonas A.M., Mooij W.E., Burgener A., Manrique Hehl T., Shrestha G.S., Horn J., et al. Oxygen Consumption with High-Flow Nasal Oxygen versus Mechanical Ventilation- An International Multicenter Observational Study in COVID-19 Patients (PROXY-COVID) Am. J. Trop. Med. Hyg. 2023:1\u20137.", "ArticleIdList": ["36972693"]}, {"Citation": "Forchette L., Sebastian W., Liu T. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. Curr. Med. Sci. 2021;41:1037\u20131051. doi: 10.1007/s11596-021-2395-1.", "ArticleIdList": ["10.1007/s11596-021-2395-1", "PMC8267225", "34241776"]}, {"Citation": "Svoboda J., Tkadlec J., Pavlogiannis A., Chatterjee K., Nowak M.A. Infection dynamics of COVID-19 virus under lockdown and reopening. Sci. Rep. 2022;12:1526. doi: 10.1038/s41598-022-05333-5.", "ArticleIdList": ["10.1038/s41598-022-05333-5", "PMC8795434", "35087091"]}, {"Citation": "Rivera L.C., Mohamed S., Salar T., Mostafa M.R., Najim M., Malik M.A., Renjithal S.L.M., Magdi M. Organizing Pneumonia: An Unusual Sequela of COVID-19 Infection. Eur. J. Case Rep. Intern. Med. 2023;10:003787. doi: 10.12890/2023_003787.", "ArticleIdList": ["10.12890/2023_003787", "PMC10035623", "36970163"]}, {"Citation": "Maliki I., Elmsellem H., Hafez B., EL Moussaoui A., Reda Kachmar M., Ouahbi A. The psychological properties of the Arabic BDI-II and the psychological state of the general Moroccan population during the mandatory quarantine due to the COVID-19 pandemic. Casp. J. Environ. Sci. 2021;19:139\u2013150."}, {"Citation": "Ahmad M.F., Mahakkanukrauh P., Das S. The Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in the Vaginal Fluid of Females With Severe Coronavirus Disease 2019 (COVID-19) Infection: Scientific Facts. Clin. Infect. Dis. 2022;74:2262\u20132263. doi: 10.1093/cid/ciaa1608.", "ArticleIdList": ["10.1093/cid/ciaa1608", "PMC7665426", "33085746"]}, {"Citation": "Chong Y.M., Chan Y.F., Jamaluddin M.F.H., Hasan M.S., Pang Y.K., Ponnampalavanar S., Syed Omar S.F., Sam I.C. Rhinovirus/enterovirus was the most common respiratory virus detected in adults with severe acute respiratory infections pre-COVID-19 in Kuala Lumpur, Malaysia. PLoS ONE. 2022;17:e0273697. doi: 10.1371/journal.pone.0273697.", "ArticleIdList": ["10.1371/journal.pone.0273697", "PMC9439195", "36054088"]}, {"Citation": "Mrcela D., Markic J., Zhao C., Viskovic D.V., Milic P., Copac R., Li Y. Changes following the Onset of the COVID-19 Pandemic in the Burden of Hospitalization for Respiratory Syncytial Virus Acute Lower Respiratory Infection in Children under Two Years: A Retrospective Study from Croatia. Viruses. 2022;14:2746. doi: 10.3390/v14122746.", "ArticleIdList": ["10.3390/v14122746", "PMC9785187", "36560751"]}, {"Citation": "Ali M.A.O., Abdalrahman N.A., Shanab E.A.I., Mohammed M.M.A., Ibrahim M.M., Abdalrahman I.B. The outcome of COVID-19 patients in the intensive care unit in Sudan: A cross-sectional study. Health Sci. Rep. 2023;6:e1161. doi: 10.1002/hsr2.1161.", "ArticleIdList": ["10.1002/hsr2.1161", "PMC10033838", "36970641"]}, {"Citation": "Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021;93:250\u2013256. doi: 10.1002/jmv.26232.", "ArticleIdList": ["10.1002/jmv.26232", "PMC7361342", "32592501"]}, {"Citation": "Nile S.H., Nile A., Qiu J., Li L., Jia X., Kai G. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66\u201370. doi: 10.1016/j.cytogfr.2020.05.002.", "ArticleIdList": ["10.1016/j.cytogfr.2020.05.002", "PMC7204669", "32418715"]}, {"Citation": "Soy M., Keser G., Atagunduz P. Pathogenesis and treatment of cytokine storm in COVID-19. Turk. J. Biol. 2021;45:372\u2013389. doi: 10.3906/biy-2105-37.", "ArticleIdList": ["10.3906/biy-2105-37", "PMC8573840", "34803441"]}, {"Citation": "Ye Q., Wang B., Mao J. The pathogenesis and treatment of the; Cytokine Storm\u2019 in COVID-19. J. Infect. 2020;80:607\u2013613. doi: 10.1016/j.jinf.2020.03.037.", "ArticleIdList": ["10.1016/j.jinf.2020.03.037", "PMC7194613", "32283152"]}, {"Citation": "Yongzhi X. COVID-19-associated cytokine storm syndrome and diagnostic principles: An old and new Issue. Emerg. Microbes Infect. 2021;10:266\u2013276. doi: 10.1080/22221751.2021.1884503.", "ArticleIdList": ["10.1080/22221751.2021.1884503", "PMC7894425", "33522893"]}, {"Citation": "Aldawsari M.F., Alalaiwe A., Khafagy E.S., Al Saqr A., Alshahrani S.M., Alsulays B.B., Alshehri S., Abu Lila A.S., Danish Rizvi S.M., Hegazy W.A.H. Efficacy of SPG-ODN 1826 Nanovehicles in Inducing M1 Phenotype through TLR-9 Activation in Murine Alveolar J774A.1 Cells: Plausible Nano-Immunotherapy for Lung Carcinoma. Int. J. Mol. Sci. 2021;22:6833. doi: 10.3390/ijms22136833.", "ArticleIdList": ["10.3390/ijms22136833", "PMC8268145", "34202080"]}, {"Citation": "Khayyat A.N., Abbas H.A., Mohamed M.F.A., Asfour H.Z., Khayat M.T., Ibrahim T.S., Youns M., Khafagy E.-S., Abu Lila A.S., Safo M.K., et al. Not Only Antimicrobial: Metronidazole Mitigates the Virulence of Proteus mirabilis Isolated from Macerated Diabetic Foot Ulcer. Appl. Sci. 2021;11:6847. doi: 10.3390/app11156847.", "ArticleIdList": ["10.3390/app11156847"]}, {"Citation": "Askoura M., Almalki A.J., Lila A.S.A., Almansour K., Alshammari F., Khafagy E.-S., Ibrahim T.S., Hegazy W.A.H. Alteration of Salmonella enterica Virulence and Host Pathogenesis through Targeting sdiA by Using the CRISPR-Cas9 System. Microorganisms. 2021;9:2564. doi: 10.3390/microorganisms9122564.", "ArticleIdList": ["10.3390/microorganisms9122564", "PMC8707642", "34946165"]}, {"Citation": "Ramasamy S., Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin. Microbiol. Rev. 2021;34:e00299-20. doi: 10.1128/CMR.00299-20.", "ArticleIdList": ["10.1128/CMR.00299-20", "PMC8142516", "33980688"]}, {"Citation": "Soy M., Keser G., Atagunduz P., Tabak F., Atagunduz I., Kayhan S. Cytokine storm in COVID-19: Pathogenesis and overview of anti-inflammatory agents used in treatment. Clin. Rheumatol. 2020;39:2085\u20132094. doi: 10.1007/s10067-020-05190-5.", "ArticleIdList": ["10.1007/s10067-020-05190-5", "PMC7260446", "32474885"]}, {"Citation": "Fara A., Mitrev Z., Rosalia R.A., Assas B.M. Cytokine storm and COVID-19: A chronicle of pro-inflammatory cytokines. Open Biol. 2020;10:200160. doi: 10.1098/rsob.200160.", "ArticleIdList": ["10.1098/rsob.200160", "PMC7536084", "32961074"]}, {"Citation": "Hu Z., Li S., Song X. Cytokine storm with rapidly elevated interleukin-6 indicates sudden death in patients with critical COVID-19. Cytokine Growth Factor Rev. 2021;58:30\u201331. doi: 10.1016/j.cytogfr.2020.08.001.", "ArticleIdList": ["10.1016/j.cytogfr.2020.08.001", "PMC7445135", "32873506"]}, {"Citation": "Conti P., Caraffa A., Tete G., Gallenga C.E., Ross R., Kritas S.K., Frydas I., Younes A., Di Emidio P., Ronconi G. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19. J. Biol. Regul. Homeost. Agents. 2020;34:1629\u20131632. doi: 10.23812/20-2EDIT.", "ArticleIdList": ["10.23812/20-2EDIT", "32945158"]}, {"Citation": "Jafrin S., Aziz M.A., Islam M.S. Elevated Levels of Pleiotropic Interleukin-6 (IL-6) and Interleukin-10 (IL-10) are Critically Involved With the Severity and Mortality of COVID-19: An Updated Longitudinal Meta-Analysis and Systematic Review on 147 Studies. Biomark. Insights. 2022;17:11772719221106600. doi: 10.1177/11772719221106600.", "ArticleIdList": ["10.1177/11772719221106600", "PMC9209786", "35747885"]}, {"Citation": "Mojtabavi H., Saghazadeh A., Rezaei N. Interleukin-6 and severe COVID-19: A systematic review and meta-analysis. Eur. Cytokine Netw. 2020;31:44\u201349. doi: 10.1684/ecn.2020.0448.", "ArticleIdList": ["10.1684/ecn.2020.0448", "PMC7530350", "32933891"]}, {"Citation": "Kitsos D., Tzartos J., Korres G., Giannopapas V., Riga M., Stergiou C., Tsoga A., Grigoropoulos C., Paraskevas G., Zompola C., et al. IL-6 Serum Levels in COVID-19 Patients With Vertigo. Cureus. 2023;15:e35042. doi: 10.7759/cureus.35042.", "ArticleIdList": ["10.7759/cureus.35042", "PMC10024114", "36942191"]}, {"Citation": "Sasson J., Moreau G.B., Petri W.A., Jr. The Role of IL-13 and the Type 2 Immune Pathway in COVID-19: A Review. Ann. Allergy Asthma Immunol. 2023 doi: 10.1016/j.anai.2023.03.009.", "ArticleIdList": ["10.1016/j.anai.2023.03.009", "PMC10014128", "36924937"]}, {"Citation": "Pinzon R.T., Wijaya V.O., Buana R.B. Interleukin-6 (IL-6) inhibitors as therapeutic agents for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. J. Infect. Public Health. 2021;14:1001\u20131009. doi: 10.1016/j.jiph.2021.06.004.", "ArticleIdList": ["10.1016/j.jiph.2021.06.004", "PMC8204364", "34153723"]}, {"Citation": "Udomsinprasert W., Jittikoon J., Sangroongruangsri S., Chaikledkaew U. Circulating Levels of Interleukin-6 and Interleukin-10, But Not Tumor Necrosis Factor-Alpha, as Potential Biomarkers of Severity and Mortality for COVID-19: Systematic Review with Meta-analysis. J. Clin. Immunol. 2021;41:11\u201322. doi: 10.1007/s10875-020-00899-z.", "ArticleIdList": ["10.1007/s10875-020-00899-z", "PMC7602765", "33128665"]}, {"Citation": "Yu S.Y., Koh D.H., Choi M., Ryoo S., Huh K., Yeom J.S., Yoon Y.K. Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: A systematic review and meta-analysis. Emerg. Microbes Infect. 2022;11:1154\u20131165. doi: 10.1080/22221751.2022.2059405.", "ArticleIdList": ["10.1080/22221751.2022.2059405", "PMC9037226", "35343397"]}, {"Citation": "Conti P., Caraffa A., Gallenga C.E., Ross R., Kritas S.K., Frydas I., Younes A., Ronconi G. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: A promising inhibitory strategy. J. Biol. Regul. Homeost. Agents. 2020;34:1971\u20131975. doi: 10.23812/20-1-E.", "ArticleIdList": ["10.23812/20-1-E", "33016027"]}, {"Citation": "Kim J.S., Lee J.Y., Yang J.W., Lee K.H., Effenberger M., Szpirt W., Kronbichler A., Shin J.I. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11:316\u2013329. doi: 10.7150/thno.49713.", "ArticleIdList": ["10.7150/thno.49713", "PMC7681075", "33391477"]}, {"Citation": "Kaps L., Labenz C., Grimm D., Schwarting A., Galle P.R., Schreiner O. Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report. Clin. Case Rep. 2020;8:2990\u20132994. doi: 10.1002/ccr3.3307.", "ArticleIdList": ["10.1002/ccr3.3307", "PMC7752410", "33363865"]}, {"Citation": "Askoura M., Abbas H.A., Al Sadoun H., Abdulaal W.H., Abu Lila A.S., Almansour K., Alshammari F., Khafagy E.-S., Ibrahim T.S., Hegazy W.A.H. Elevated Levels of IL-33, IL-17 and IL-25 Indicate the Progression from Chronicity to Hepatocellular Carcinoma in Hepatitis C Virus Patients. Pathogens. 2022;11:57. doi: 10.3390/pathogens11010057.", "ArticleIdList": ["10.3390/pathogens11010057", "PMC8781674", "35056005"]}, {"Citation": "Conti P., Ronconi G., Caraffa A., Gallenga C.E., Ross R., Frydas I., Kritas S.K. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): Anti-inflammatory strategies. J. Biol. Regul. Homeost. Agents. 2020;34:327\u2013331. doi: 10.23812/CONTI-E.", "ArticleIdList": ["10.23812/CONTI-E", "32171193"]}, {"Citation": "Hegazy W.A.H., Henaway M. Hepatitis C virus pathogenesis: Serum IL-33 level indicates liver damage. Afr. J. Microbiol. Res. 2015;9:1386\u20131393. doi: 10.5897/AJMR2015.7496.", "ArticleIdList": ["10.5897/AJMR2015.7496"]}, {"Citation": "Rondovic G., Djordjevic D., Udovicic I., Stanojevic I., Zeba S., Abazovic T., Vojvodic D., Abazovic D., Khan W., Surbatovic M. From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19? Biomedicines. 2022;10:2620. doi: 10.3390/biomedicines10102620.", "ArticleIdList": ["10.3390/biomedicines10102620", "PMC9599155", "36289881"]}, {"Citation": "Han Q., Guo M., Zheng Y., Zhang Y., De Y., Xu C., Zhang L., Sun R., Lv Y., Liang Y., et al. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis. Front. Pharmacol. 2020;11:615972. doi: 10.3389/fphar.2020.615972.", "ArticleIdList": ["10.3389/fphar.2020.615972", "PMC7769953", "33384605"]}, {"Citation": "Bovet M., Wadsack D., Kosely F., Zink W., Zahn R. Fatal course of COVID-19 despite IL-6 receptor blockade in cytokine storm: Perimyocarditis and coagulopathy after administration of tocilizumab. Anaesthesist. 2021;70:121\u2013126. doi: 10.1007/s00101-020-00871-x.", "ArticleIdList": ["10.1007/s00101-020-00871-x", "PMC7563901", "33064176"]}, {"Citation": "Emsley H., Smith C., Georgiou R., Vail A., Hopkins S., Rothwell N., Tyrrell P. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J. Neurol. Neurosurg. Psychiatry. 2005;76:1366\u20131372. doi: 10.1136/jnnp.2004.054882.", "ArticleIdList": ["10.1136/jnnp.2004.054882", "PMC1739363", "16170078"]}, {"Citation": "M\u00f6ller B., Villiger P.M. Springer Seminars in Immunopathology. Springer; Berlin/Heidelberg, Germany: 2006. Inhibition of IL-1, IL-6, and TNF-\u03b1 in immune-mediated inflammatory diseases; pp. 391\u2013408.", "ArticleIdList": ["16738952"]}, {"Citation": "Scherger S., Henao-Mart\u00ednez A., Franco-Paredes C., Shapiro L. Rethinking interleukin-6 blockade for treatment of COVID-19. Med. Hypotheses. 2020;144:110053. doi: 10.1016/j.mehy.2020.110053.", "ArticleIdList": ["10.1016/j.mehy.2020.110053", "PMC7320867", "32758889"]}, {"Citation": "Atal S., Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: A promising therapy? Pharm. Med. 2020;34:223\u2013231. doi: 10.1007/s40290-020-00342-z.", "ArticleIdList": ["10.1007/s40290-020-00342-z", "PMC7292936", "32535732"]}, {"Citation": "Khayyat A.N., Abbas H.A., Khayat M.T., Shaldam M.A., Askoura M., Asfour H.Z., Khafagy E.-S., Abu Lila A.S., Allam A.N., Hegazy W.A.H. Secnidazole Is a Promising Imidazole Mitigator of Serratia marcescens Virulence. Microorganisms. 2021;9:2333. doi: 10.3390/microorganisms9112333.", "ArticleIdList": ["10.3390/microorganisms9112333", "PMC8617784", "34835458"]}, {"Citation": "Bertoni A., Penco F., Mollica H., Bocca P., Prigione I., Corcione A., Cangelosi D., Schena F., Del Zotto G., Amaro A., et al. Spontaneous NLRP3 inflammasome-driven IL-1-beta secretion is induced in severe COVID-19 patients and responds to anakinra treatment. J. Allergy Clin. Immunol. 2022;150:796\u2013805. doi: 10.1016/j.jaci.2022.05.029.", "ArticleIdList": ["10.1016/j.jaci.2022.05.029", "PMC9272569", "35835255"]}, {"Citation": "Cavalli G., Dagna L. The right place for IL-1 inhibition in COVID-19. Lancet Respir. Med. 2021;9:223\u2013224. doi: 10.1016/S2213-2600(21)00035-7.", "ArticleIdList": ["10.1016/S2213-2600(21)00035-7", "PMC7826019", "33493449"]}, {"Citation": "Della-Torre E., Criscuolo E., Lanzillotta M., Locatelli M., Clementi N., Mancini N., Dagna L., COVID-BioB study group IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19. Lancet Rheumatol. 2021;3:e829\u2013e831. doi: 10.1016/S2665-9913(21)00321-0.", "ArticleIdList": ["10.1016/S2665-9913(21)00321-0", "PMC8555969", "34746843"]}, {"Citation": "Della-Torre E., Lanzillotta M., Campochiaro C., Cavalli G., De Luca G., Tomelleri A., Boffini N., De Lorenzo R., Ruggeri A., Rovere-Querini P., et al. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Front. Immunol. 2021;12:675678. doi: 10.3389/fimmu.2021.675678.", "ArticleIdList": ["10.3389/fimmu.2021.675678", "PMC8117339", "33995419"]}, {"Citation": "Franzetti M., Forastieri A., Borsa N., Pandolfo A., Molteni C., Borghesi L., Pontiggia S., Evasi G., Guiotto L., Erba M., et al. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study. J. Immunol. 2021;206:1569\u20131575. doi: 10.4049/jimmunol.2001126.", "ArticleIdList": ["10.4049/jimmunol.2001126", "PMC7980530", "33547169"]}, {"Citation": "Makaremi S., Asgarzadeh A., Kianfar H., Mohammadnia A., Asghariazar V., Safarzadeh E. The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19. Inflamm. Res. 2022;71:923\u2013947. doi: 10.1007/s00011-022-01596-w.", "ArticleIdList": ["10.1007/s00011-022-01596-w", "PMC9243884", "35751653"]}, {"Citation": "Renieris G., Karakike E., Gkavogianni T., Droggiti D.E., Stylianakis E., Andriopoulou T., Spanou V.M., Kafousopoulos D., Netea M.G., Eugen-Olsen J., et al. IL-1 Mediates Tissue-Specific Inflammation and Severe Respiratory Failure in COVID-19. J. Innate Immun. 2022;14:644\u2013657. doi: 10.1159/000524560.", "ArticleIdList": ["10.1159/000524560", "PMC9801253", "35545011"]}, {"Citation": "van de Veerdonk F.L., Netea M.G. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit. Care. 2020;24:445. doi: 10.1186/s13054-020-03166-0.", "ArticleIdList": ["10.1186/s13054-020-03166-0", "PMC7411343", "32682440"]}, {"Citation": "Cassat J.E., Skaar E.P. Iron in infection and immunity. Cell Host Microbe. 2013;13:509\u2013519. doi: 10.1016/j.chom.2013.04.010.", "ArticleIdList": ["10.1016/j.chom.2013.04.010", "PMC3676888", "23684303"]}, {"Citation": "Haschka D., Hoffmann A., Weiss G. Iron in immune cell function and host defense. Semin. Cell Dev. Biol. 2021;115:27\u201336. doi: 10.1016/j.semcdb.2020.12.005.", "ArticleIdList": ["10.1016/j.semcdb.2020.12.005", "33386235"]}, {"Citation": "Alroomi M., Rajan R., Omar A.A., Alsaber A., Pan J., Fatemi M., Zhanna K.D., Aboelhassan W., Almutairi F., Alotaibi N., et al. Ferritin level: A predictor of severity and mortality in hospitalized COVID-19 patients. Immun. Inflamm. Dis. 2021;9:1648\u20131655. doi: 10.1002/iid3.517.", "ArticleIdList": ["10.1002/iid3.517", "PMC8589386", "34438471"]}, {"Citation": "Dahan S., Segal G., Katz I., Hellou T., Tietel M., Bryk G., Amital H., Shoenfeld Y., Dagan A. Ferritin as a marker of severity in COVID-19 patients: A fatal correlation. Isr. Med. Assoc. J. IMAJ. 2020;22:494\u2013500.", "ArticleIdList": ["33236582"]}, {"Citation": "Lin Z., Long F., Yang Y., Chen X., Xu L., Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J. Infect. 2020;81:647\u2013679. doi: 10.1016/j.jinf.2020.06.053.", "ArticleIdList": ["10.1016/j.jinf.2020.06.053", "PMC7313486", "32592705"]}, {"Citation": "Mahroum N., Alghory A., Kiyak Z., Alwani A., Seida R., Alrais M., Shoenfeld Y. Ferritin\u2013from iron, through inflammation and autoimmunity, to COVID-19. J. Autoimmun. 2022;126:102778. doi: 10.1016/j.jaut.2021.102778.", "ArticleIdList": ["10.1016/j.jaut.2021.102778", "PMC8647584", "34883281"]}, {"Citation": "Dupuis C., de Montmollin E., Buetti N., Goldgran-Toledano D., Reignier J., Schwebel C., Domitile J., Neuville M., Ursino M., Siami S. Impact of early corticosteroids on 60-day mortality in critically ill patients with COVID-19: A multicenter cohort study of the OUTCOMEREA network. PLoS ONE. 2021;16:e0255644. doi: 10.1371/journal.pone.0255644.", "ArticleIdList": ["10.1371/journal.pone.0255644", "PMC8336847", "34347836"]}, {"Citation": "Moreno A., Vargas C., Azocar F., Villarroel F., Cofr\u00e9 M., Oppliger H., R\u00edos F., Raijmakers M., Silva-Ayarza I., Beltr\u00e1n C. Steroids and mortality in non-critically ill COVID-19 patients: A propensity score-weighted study in a Chilean cohort. Int. J. Infect. Dis. 2021;112:124\u2013129. doi: 10.1016/j.ijid.2021.09.038.", "ArticleIdList": ["10.1016/j.ijid.2021.09.038", "PMC8450146", "34547488"]}, {"Citation": "Corominas H., Castellv\u00ed I., Pomar V., Antonijoan R., Mur I., Matas L., Gich I., de Benito N., Laiz A., Castillo D. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. Clin. Immunol. 2021;223:108631. doi: 10.1016/j.clim.2020.108631.", "ArticleIdList": ["10.1016/j.clim.2020.108631", "PMC7658611", "33189888"]}, {"Citation": "Hashimoto S., Yoshizaki K., Uno K., Kitajima H., Arai T., Tamura Y., Morishita H., Matsuoka H., Han Y., Minamoto S. Prompt reduction in CRP, IL-6, IFN-\u03b3, IP-10, and MCP-1 and a relatively low basal ratio of ferritin/CRP is possibly associated with the efficacy of tocilizumab Monotherapy in severely to critically ill patients with COVID-19. Front. Med. 2021;8:734838. doi: 10.3389/fmed.2021.734838.", "ArticleIdList": ["10.3389/fmed.2021.734838", "PMC8494777", "34631752"]}, {"Citation": "Ahmed M.H., Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): A review. SN Compr. Clin. Med. 2020;2:2637\u20132646. doi: 10.1007/s42399-020-00610-8.", "ArticleIdList": ["10.1007/s42399-020-00610-8", "PMC7599121", "33163859"]}, {"Citation": "Horby P., Lim W.S., Emberson J., Mafham M., Bell J., Linsell L., Staplin N., Brightling C., Ustianowski A., Elmahi E. Effect of dexamethasone in hospitalized patients with COVID-19\u2013preliminary report. MedRxiv. 2020 doi: 10.1101/2020.06.22.20137273.", "ArticleIdList": ["10.1101/2020.06.22.20137273"]}, {"Citation": "Albani F., Fusina F., Granato E., Capotosto C., Ceracchi C., Gargaruti R., Santangelo G., Schiavone L., Taranto M.S., Tosati C. Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients. Sci. Rep. 2021;11:1\u20136. doi: 10.1038/s41598-020-80654-x.", "ArticleIdList": ["10.1038/s41598-020-80654-x", "PMC7806743", "33441909"]}, {"Citation": "Guz D., Gafter-Gvili A., Lev N., Levin G.S., Lev S. Tocilizumab Treatment Effect on Iron Homeostasis in Severe COVID-19 Patients. Acta Haematol. 2022;145:440\u2013447. doi: 10.1159/000522307.", "ArticleIdList": ["10.1159/000522307", "PMC9059034", "35100583"]}, {"Citation": "Navarro-Mill\u00e1n I., Sattui S.E., Lakhanpal A., Zisa D., Siegel C.H., Crow M.K. Use of anakinra to prevent mechanical ventilation in severe COVID-19: A case series. Arthritis Rheumatol. 2020;72:1990\u20131997. doi: 10.1002/art.41422.", "ArticleIdList": ["10.1002/art.41422", "PMC7361793", "32602262"]}, {"Citation": "Kyriazopoulou E., Huet T., Cavalli G., Gori A., Kyprianou M., Pickkers P., Eugen-Olsen J., Clerici M., Veas F., Chatellier G. Effect of anakinra on mortality in patients with COVID-19: A systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3:e690\u2013e697. doi: 10.1016/S2665-9913(21)00216-2.", "ArticleIdList": ["10.1016/S2665-9913(21)00216-2", "PMC8352496", "34396156"]}, {"Citation": "Rostami M., Mansouritorghabeh H. D-dimer level in COVID-19 infection: A systematic review. Expert Rev. Hematol. 2020;13:1265\u20131275. doi: 10.1080/17474086.2020.1831383.", "ArticleIdList": ["10.1080/17474086.2020.1831383", "32997543"]}, {"Citation": "Alzoughool F., Alanagreh L.a., Abumweis S., Atoum M. Cerebrovascular comorbidity, high blood levels of C-reactive protein and D-dimer are associated with disease outcomes in COVID-19 patients. Clin. Hemorheol. Microcirc. 2021;77:311\u2013322. doi: 10.3233/CH-201002.", "ArticleIdList": ["10.3233/CH-201002", "33185593"]}, {"Citation": "Takahashi H., Iwasaki Y., Watanabe T., Ichinose N., Oda T. Pulmonary embolism after dexamethasone treatment for COVID-19: A case report. BMC Infect. Dis. 2022;22:277. doi: 10.1186/s12879-022-07228-2.", "ArticleIdList": ["10.1186/s12879-022-07228-2", "PMC8938737", "35317729"]}, {"Citation": "Wenban C., Heer R.S., Baktash V., Kandiah P., Katsanouli T., Pandey A., Goindoo R., Ajaz A., Van den Abbeele K., Mandal A.K. Dexamethasone treatment may mitigate adverse effects of vitamin D deficiency in hospitalized COVID-19 patients. J. Med. Virol. 2021;93:6605\u20136610. doi: 10.1002/jmv.27215.", "ArticleIdList": ["10.1002/jmv.27215", "PMC8426812", "34273116"]}, {"Citation": "Sarfraz A., Sarfraz Z., Razzack A.A., Patel G., Sarfraz M. Venous thromboembolism, corticosteroids and COVID-19: A systematic review and meta-analysis. Clin. Appl. Thromb./Hemost. 2021;27:1076029621993573. doi: 10.1177/1076029621993573.", "ArticleIdList": ["10.1177/1076029621993573", "PMC7883150", "33571009"]}, {"Citation": "Lu C., Liu Y., Chen B., Yang H., Hu H., Liu Y., Zhao Y. Prognostic value of lymphocyte count in severe COVID-19 patients with corticosteroid treatment. Signal Transduct. Target. Ther. 2021;6:106. doi: 10.1038/s41392-021-00517-3.", "ArticleIdList": ["10.1038/s41392-021-00517-3", "PMC7921828", "33654057"]}, {"Citation": "Marrone A., Nevola R., Sellitto A., Cozzolino D., Romano C., Cuomo G., Aprea C., Schwartzbaum M.X.P., Ricozzi C., Imbriani S. Remdesivir plus dexamethasone versus dexamethasone alone for the treatment of COVID-19 patients requiring supplemental O2 therapy: A prospective controlled non-randomized study. Clin. Infect. Dis. 2022;75:e403\u2013e409. doi: 10.1093/cid/ciac014.", "ArticleIdList": ["10.1093/cid/ciac014", "PMC8807307", "35084022"]}, {"Citation": "Ip A., Berry D.A., Hansen E., Goy A.H., Pecora A.L., Sinclaire B.A., Bednarz U., Marafelias M., Berry S.M., Berry N.S. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients\u2014An observational study. PLoS ONE. 2020;15:e0237693. doi: 10.1371/journal.pone.0237693.", "ArticleIdList": ["10.1371/journal.pone.0237693", "PMC7425928", "32790733"]}, {"Citation": "Salama C., Han J., Yau L., Reiss W.G., Kramer B., Neidhart J.D., Criner G.J., Kaplan-Lewis E., Baden R., Pandit L., et al. Tocilizumab in Patients Hospitalized with COVID-19 Pneumonia. N. Engl. J. Med. 2021;384:20\u201330. doi: 10.1056/NEJMoa2030340.", "ArticleIdList": ["10.1056/NEJMoa2030340", "PMC7781101", "33332779"]}, {"Citation": "Mariette X., Hermine O., Tharaux P.-L., Resche-Rigon M., Porcher R., Ravaud P., Bureau S., Dougados M., Tibi A., Azoulay E. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatol. 2022;4:e24\u2013e32. doi: 10.1016/S2665-9913(21)00315-5.", "ArticleIdList": ["10.1016/S2665-9913(21)00315-5", "PMC8598187", "34812424"]}, {"Citation": "Balkhair A., Al-Zakwani I., Al Busaidi M., Al-Khirbash A., Al Mubaihsi S., BaTaher H., Al Aghbari J., Al Busaidi I., Al Kindi M., Baawain S. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int. J. Infect. Dis. 2021;103:288\u2013296. doi: 10.1016/j.ijid.2020.11.149.", "ArticleIdList": ["10.1016/j.ijid.2020.11.149", "PMC7670920", "33217576"]}, {"Citation": "Naveed Z., Sarwar M., Ali Z., Saeed D., Choudhry K., Sarfraz A., Sarfraz Z., Felix M., Cherrez-Ojeda I. Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis. J. Clin. Lab. Anal. 2022;36:e24434. doi: 10.1002/jcla.24434.", "ArticleIdList": ["10.1002/jcla.24434", "PMC9110982", "35435272"]}, {"Citation": "Khani E., Shahrabi M., Rezaei H., Pourkarim F., Afsharirad H., Solduzian M. Current evidence on the use of anakinra in COVID-19. Int. Immunopharmacol. 2022;111:109075. doi: 10.1016/j.intimp.2022.109075.", "ArticleIdList": ["10.1016/j.intimp.2022.109075", "PMC9296834", "35905562"]}, {"Citation": "Ding J., Karp J.E., Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: Interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19:353\u2013363. doi: 10.3233/CBM-160336.", "ArticleIdList": ["10.3233/CBM-160336", "28582845"]}, {"Citation": "Robertson S.J., Ammann C.G., Messer R.J., Carmody A.B., Myers L., Dittmer U., Nair S., Gerlach N., Evans L.H., Cafruny W.A. Suppression of acute anti-friend virus CD8+ T-cell responses by coinfection with lactate dehydrogenase-elevating virus. J. Virol. 2008;82:408\u2013418. doi: 10.1128/JVI.01413-07.", "ArticleIdList": ["10.1128/JVI.01413-07", "PMC2224392", "17959678"]}, {"Citation": "Henry B.M., Aggarwal G., Wong J., Benoit S., Vikse J., Plebani M., Lippi G. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. Am. J. Emerg. Med. 2020;38:1722\u20131726. doi: 10.1016/j.ajem.2020.05.073.", "ArticleIdList": ["10.1016/j.ajem.2020.05.073", "PMC7251362", "32738466"]}, {"Citation": "Levine S.J., Wu T., Shelhamer J.H. Extracellular release of the type I intracellular IL-1 receptor antagonist from human airway epithelial cells: Differential effects of IL-4, IL-13, IFN-gamma, and corticosteroids. J. Immunol. (Baltim. Md. 1950) 1997;158:5949\u20135957. doi: 10.4049/jimmunol.158.12.5949.", "ArticleIdList": ["10.4049/jimmunol.158.12.5949", "9190949"]}, {"Citation": "Perregaux D., Barberia J., Lanzetti A.J., Geoghegan K.F., Carty T., Gabel C. IL-1 beta maturation: Evidence that mature cytokine formation can be induced specifically by nigericin. J. Immunol. (Baltim. Md. 1950) 1992;149:1294\u20131303. doi: 10.4049/jimmunol.149.4.1294.", "ArticleIdList": ["10.4049/jimmunol.149.4.1294", "1500719"]}, {"Citation": "Pontali E., Volpi S., Signori A., Antonucci G., Castellaneta M., Buzzi D., Montale A., Bustaffa M., Angelelli A., Caorsi R. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia. J. Allergy Clin. Immunol. 2021;147:1217\u20131225. doi: 10.1016/j.jaci.2021.01.024.", "ArticleIdList": ["10.1016/j.jaci.2021.01.024", "PMC7865089", "33556464"]}, {"Citation": "Pinz\u00f3n M.A., Ortiz S., Holgu\u00edn H., Betancur J.F., Cardona Arango D., Laniado H., Arias Arias C., Mu\u00f1oz B., Quiceno J., Jaramillo D. Dexamethasone vs methylprednisolone high dose for COVID-19 pneumonia. PLoS ONE. 2021;16:e0252057. doi: 10.1371/journal.pone.0252057.", "ArticleIdList": ["10.1371/journal.pone.0252057", "PMC8148307", "34033648"]}, {"Citation": "Yildirim F., Erdogan M., Mutlu M., Icacan O., Onar M., Bes C. Efficacy of anticytokine treatments added to corticosteroids in patients with COVID-19-associated pneumonia and hyperinflammation: A single center experience. Eur. Rev. Med. Pharmacol. Sci. 2022;26:7297\u20137304.", "ArticleIdList": ["36263542"]}, {"Citation": "Sarhan R.M., Harb H.S., Abou Warda A.E., Salem-Bekhit M.M., Shakeel F., Alzahrani S.A., Madney Y.M., Boshra M.S. Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. J. Infect. Public Health. 2022;15:116\u2013122. doi: 10.1016/j.jiph.2021.10.024.", "ArticleIdList": ["10.1016/j.jiph.2021.10.024", "PMC8562044", "34764044"]}, {"Citation": "Fern\u00e1ndez-Ruiz M., L\u00f3pez-Medrano F., P\u00e9rez-Jacoiste As\u00edn M.A., Maestro de la Calle G., Bueno H., Caro-Teller J.M., Catalan M., de la Calle C., Garc\u00eda-Garc\u00eda R., G\u00f3mez C. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. J. Med. Virol. 2021;93:831\u2013842. doi: 10.1002/jmv.26308.", "ArticleIdList": ["10.1002/jmv.26308", "PMC7404673", "32672860"]}, {"Citation": "Zar\u0119bska-Michaluk D., Jaroszewicz J., Rogalska M., Martonik D., Pabjan P., Berkan-Kawi\u0144ska A., Bolewska B., Oczko-Grzesik B., Kozielewicz D., Tudrujek-Zdunek M. Effectiveness of tocilizumab with and without dexamethasone in patients with severe COVID-19: A retrospective study. J. Inflamm. Res. 2021;14:3359. doi: 10.2147/JIR.S322645.", "ArticleIdList": ["10.2147/JIR.S322645", "PMC8291861", "34295173"]}, {"Citation": "Edalatifard M., Akhtari M., Salehi M., Naderi Z., Jamshidi A., Mostafaei S., Najafizadeh S.R., Farhadi E., Jalili N., Esfahani M. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: Results from a randomised controlled clinical trial. Eur. Respir. J. 2020;56:2002808. doi: 10.1183/13993003.02808-2020.", "ArticleIdList": ["10.1183/13993003.02808-2020", "PMC7758541", "32943404"]}, {"Citation": "Ajeganova S., De Becker A., Schots R. Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still\u2019s disease: When dosage matters in overcoming secondary therapy resistance. Ther. Adv. Musculoskelet. Dis. 2020;12:1759720X20974858. doi: 10.1177/1759720X20974858.", "ArticleIdList": ["10.1177/1759720X20974858", "PMC7692351", "33281955"]}, {"Citation": "Kumakura S., Murakawa Y. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol. 2014;66:2297\u20132307. doi: 10.1002/art.38672.", "ArticleIdList": ["10.1002/art.38672", "PMC4271677", "24756912"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "3", "Day": "13"}, {"Year": "2023", "Month": "3", "Day": "29"}, {"Year": "2023", "Month": "3", "Day": "30"}, {"Year": "2023", "Month": "4", "Day": "14", "Hour": "6", "Minute": "1"}, {"Year": "2023", "Month": "4", "Day": "13", "Hour": "1", "Minute": "9"}, {"Year": "2023", "Month": "4", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "4", "Day": "3"}], "PublicationStatus": "epublish", "ArticleIdList": ["37046952", "PMC10094110", "10.3390/healthcare11071025", "healthcare11071025"]}}], "PubmedBookArticle": []}